Two developments in GLP-1 research were tracked this week, and both speak to a common frustration: these medications do not work the same way for everyone. One trial looked at combining drugs for liver disease in type 2 diabetes. The other is trying to explain why the same oral pill can produce very different results from person to person. Together, they point toward more personalized approaches down the road.
A completed Phase 4 trial tested semaglutide combined with empagliflozin in people with type 2 diabetes and liver disease, specifically NASH. The trial has finished, but its results have not yet been published, so there is nothing to report yet about whether the combination worked better than either drug alone. This matters because NASH and type 2 diabetes often occur together, and doctors currently have limited options for treating both at once. Readers managing both conditions may want to watch for these results once they become available, since a combined approach could eventually change how liver disease is treated alongside diabetes.
Massachusetts General Hospital is recruiting 125 participants for a study asking why oral semaglutide, sold as Rybelsus, produces such different results from one person to the next. The study is called GLUCOSE-MGH, and it is designed to look at genetic differences that may explain this variation. If the researchers find a clear genetic link, it could eventually help doctors predict who is likely to respond well to the oral form of semaglutide before they start treatment. For now, the study is still in the recruiting phase, so any findings are a way off, but the question itself reflects something many patients have already noticed: this medication does not affect everyone the same way.
Neither of these trials has produced results yet, so there is no new treatment guidance to act on today. Still, it is worth keeping an eye on both. If you have NASH and type 2 diabetes, the completed trial on semaglutide plus empagliflozin may eventually inform how your care team approaches treatment. If you take or are considering Rybelsus and have wondered why it seems to work differently for different people, the MGH study may eventually offer an answer, and it is currently recruiting participants for those who want to take part directly.
Key details
A completed trial combined semaglutide with empagliflozin for liver disease in type 2…
MGH is recruiting 125 participants to study how genetic differences affect the way oral…
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-07-07